Claims for Patent: 8,722,084

Summary for Patent: 8,722,084

Title:	Controlled release preparation
Abstract:	A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.
Inventor(s):	Akiyama; Yohko (Osaka, JP), Kurasawa; Takashi (Osaka, JP), Bando; Hiroto (Osaka, JP), Nagahara; Naoki (Osaka, JP)
Assignee:	Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:	12/832,683
Patent Claims:	1. A capsule comprising: composition (i) comprising a tablet, granule or fine granule in which a release of an active ingredient is controlled; said tablet, granule or fine granule comprising a core particle containing an imidazole compound represented by formula (I'): ##STR00141## wherein ring C' is an optionally substituted benzene ring or an optionally substituted aromatic monocyclic heterocyclic ring, R.sup.0 is a hydrogen atom, an optionally substituted aralkyl group, acyl group or acyloxy group, R.sup.1, R.sup.2 and R.sup.3 are the same or different and are a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted amino group, and Y represents a nitrogen atom or CH; or a salt thereof or an optically active isomer thereof as the active ingredient, and a pH-dependently soluble release-controlled coating-layer which comprises one kind of polymeric substance or a mixture of two or more kinds of polymeric substances having different release properties selected from the group consisting of hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, carboxymethylethyl cellulose, methyl methacrylate-methacrylic acid copolymer, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl acrylate-methyl methacrylate copolymer, hydroxypropyl cellulose acetate succinate, polyvinyl acetate phthalate and shellac, wherein the active ingredient is released at an elution rate of 10% or less for 5 hours in a solution of pH 6.0, and 5% or less for one hour and 60% or more for 8 hours in a solution of pH 6.8, and composition (ii) comprising a tablet, granule or fine granule comprising a core particle containing the active ingredient and enteric coat, such that the active ingredient is released in the pH range of no less than 5.0 to no more than 6.0, wherein the composition (i) and the composition (ii) in the capsule individually contain a sufficient amount of the imidazole compound represented by formula (I') to raise a plasma level of the imidazole compound represented by formula (I') in a mammal to whom the capsule is administered to at least 100 ng/ml. 2. The capsule according to claim 1, wherein the plasma level of at least 100 ng/ml in the mammal continues for at least 8 hours. 3. The capsule according to claim 1, wherein the composition (i) and the composition (ii) in the capsule individually contain a sufficient amount of the imidazole compound represented by formula (I') to raise the plasma level in the mammal to at least 300 ng/ml. 4. A capsule comprising: composition (i) comprising a tablet, granule or fine granule in which a release of an active ingredient is controlled; said tablet, granule or fine granule comprising a core particle containing an imidazole compound represented by formula (I'): ##STR00142## wherein ring C' is an optionally substituted benzene ring or an optionally substituted aromatic monocyclic heterocyclic ring, R.sup.0 is a hydrogen atom, an optionally substituted aralkyl group, acyl group or acyloxy group, R.sup.1, R.sup.2 and R.sup.3 are the same or different and are a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted amino group, and Y represents a nitrogen atom or CH; or a salt thereof or an optically active isomer thereof as the active ingredient, and a pH-dependently soluble release-controlled coating-layer which comprises one kind of polymeric substance or a mixture of two or more kinds of polymeric substances having different release properties, selected from the group consisting of hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, carboxymethylethyl cellulose, methyl methacrylate-methacrylic acid copolymer, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl acrylate-methyl methacrylate copolymer, hydroxypropyl cellulose acetate succinate, polyvinyl acetate phthalate and shellac, wherein the active ingredient is released at an elution rate of 10% or less for 5 hours in a solution of pH 6.0, and 5% or less for one hour and 60% or more for 8 hours in a solution of pH 6.8, and composition (ii) comprising a tablet, granule or fine granule comprising a core particle containing the active ingredient and enteric coat, such that the active ingredient is released in the pH range of no less than 5.0 to no more than 6.0, wherein the imidazole compound represented by formula (I') contained in the composition (i) and the composition (ii) in the capsule is released from the capsule in a pulsatile manner, wherein the plasma level of the imidazole compound released from each of the composition (i) and the composition (ii) rises to at least 100 ng/ml in a mammal to whom the capsule is administered. 5. The capsule according to claim 4, wherein a plasma level of the imidazole compound released from each of the compositions (i) and the composition (ii) rises to at least 300 ng/ml in a mammal to whom the capsule is administered. 6. A capsule comprising: composition (i) comprising a tablet, granule or fine granule in which a release of an active ingredient is controlled; said tablet, granule or fine granule comprising a core particle containing an imidazole compound represented by formula (I'): ##STR00143## wherein ring C' is an optionally substituted benzene ring or an optionally substituted aromatic monocyclic heterocyclic ring, R.sup.0 is a hydrogen atom, an optionally substituted aralkyl group, acyl group or acyloxy group, R.sup.1, R.sup.2 and R.sup.3 are the same or different and are a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted amino group, and Y represents a nitrogen atom or CH; or a salt thereof or an optically active isomer thereof as the active ingredient, and a pH-dependently soluble release-controlled coating-layer which comprises one kind of polymeric substance or a mixture of two or more kinds of polymeric substances having different release properties selected from the group consisting of hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, carboxymethylethyl cellulose, methyl methacrylate-methacrylic acid copolymer, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl acrylate-methyl methacrylate copolymer, hydroxypropyl cellulose acetate succinate, polyvinyl acetate phthalate and shellac, wherein the active ingredient is released at an elution rate of 10% or less for 5 hours in a solution ofpH 6.0, and 5% or less for one hour and 60% or more for 8 hours in a solution of pH 6.8, and composition (ii) comprising a tablet, granule or fine granule comprising a core particle containing the active ingredient and enteric coat, such that the active ingredient is released in the pH range of no less than 5.0 to no more than 6.0, wherein an amount of the imidazole compound represented by formula (I') in the composition (i) is at least 50% more than an amount of the imidazole compound in the composition (ii), wherein the composition (i) and the composition (ii) in the capsule individually contain a sufficient amount of imidazole compound represented by formula (I') to raise the plasma level of the imidazole compound represented by formula (I') in a mammal to whom the capsule is administered to at least 100 ng/ml. 7. The capsule according to claim 6, wherein the amount of the imidazole compound contained in the composition (i) is at least twice the amount of the imidazole compound contained in the composition (ii). 8. The capsule according to claim 6, wherein the amount of the imidazole compound contained in the composition (i) is at least three times the amount of the imidazole compound contained in the composition (ii). 9. A capsule comprising: composition (i) comprising a tablet, granule or fine granule in which a release of an active ingredient is controlled; said tablet, granule or fine granule comprising a core particle containing an imidazole compound represented by formula (I'): ##STR00144## wherein ring C' is an optionally substituted benzene ring or an optionally substituted aromatic monocyclic heterocyclic ring, R.sup.0 is a hydrogen atom, an optionally substituted aralkyl group, acyl group or acyloxy group, R.sup.1, R.sup.2 and R.sup.3 are the same or different and are a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted amino group, and Y represents a nitrogen atom or CH; or a salt thereof or an optically active isomer thereof as the active ingredient, and a pH-dependently soluble release-controlled coating-layer which comprises one kind of polymeric substance or a mixture of two or more kinds of polymeric substances having different release properties selected from the group consisting of hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, carboxymethylethyl cellulose, methyl methacrylate-methacrylic acid copolymer, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl acrylate-methyl methacrylate copolymer, hydroxypropyl cellulose acetate succinate, polyvinyl acetate phthalate and shellac, wherein the active ingredient is released at an elution rate of 10% or less for 5 hours in a solution of pH 6.0, and 5% or less for one hour and 60% or more for 8 hours in a solution of pH 6.8, and composition (ii) comprising a tablet, granule or fine granule comprising a core particle containing the active ingredient and enteric coat, such that the active ingredient is released in the pH range of no less than 5.0 to no more than 6.0, wherein a total amount of the imidazole compound represented by formula (I') in the composition (i) and the composition (ii) is between 5 mg and 150 mg, wherein the composition (i) and the composition (ii) in the capsule individually contain a sufficient amount of imidazole compound represented by formula (I') to raise the plasma level of the imidazole compound represented by formula (I') in a mammal to whom the capsule is administered to at least 100 ng/ml. 10. The capsule according to claim 9, wherein the total amount of the imidazole compound represented by formula (I') in the composition (i) and the composition (ii) is between 30 mg and 90 mg. 11. The capsule according to claim 4, wherein the capsule provides two plasma level peaks in a mammal to whom the capsule is administered and a plasma level lower than the plasma level peaks is present between the two plasma level peaks.